Archive · 3 Oct 2025
Lupin Launches Blood Sugar Injection and Receives Approvals
Imagine a company called Lupin that makes medicine.
They just released a new shot in the US called Liraglutide to help people with type 2 diabetes control their blood sugar.
It's like a copy of another medicine called Victoza, which makes a lot of money.
Lupin also got the green light to sell another medicine called Rivaroxaban for people who need it.
It is for treating and preventing blood clots in kids, and adults.
Also, Lupin received a tentative approval for their version of a tablet, called Biktarvy, for people with HIV.
It's like they're making important medicines more available.
However, on one day, the company's stock went down a little bit.
Lupin Ltd launched Liraglutide injection in the US for type 2 diabetes.
The Liraglutide injection is bioequivalent to Novo Nordisk's Victoza®.
Lupin received USFDA approval for Rivaroxaban for Oral Suspension.
Approval was received for a generic version of Biktarvy® tablets.
Lupin's stock decreased by 0.32% on October 3rd.
- Who
- Lupin Ltd
- What
- Launched Liraglutide injection, received FDA approvals for Rivaroxaban and a generic version of Biktarvy tablets.
- When
- October 3rd
- Where
- United States
- Why
- To enhance its pharmaceutical portfolio and provide accessible therapies.
- Company
- Lupin Ltd
- Product Launch
- Liraglutide injection
- Target Condition
- Type 2 diabetes
- FDA Approval
- Rivaroxaban for Oral Suspension
- Generic Approval
- Biktarvy tablets
- Stock Performance
- Shares down 0.32%